A team sport: Update on neurocutaneous melanocytosis

Speaker: Yasmin Khakoo, MD, FCNS, FAAN, FAAP
When: Saturday, July 12, 2025
Time: 09:00 AM Eastern Time ( US/ Canada )
Click here to Regsiter

About Topic:
Neurocutaneous melanocytosis (NCM), a rare condition familiar to many child neurologists who care for patients with other neurocutaneous syndromes, is characterized by excessive proliferation of melanocytes along the neuraxis in conjunction with large or multiple small congenital melanocytic nevi. Biopsies of LCMN or NCM often demonstrate NRAS mutations in
codon 61 (NRAS Q61K or NRAS Q61R). A small percentage of NCM patients develop central nervous system (CNS) melanoma. Non-NCM melanomas are driven by BRAF mutations, for which many successful treatments exist. The NRAS pathway has fewer targeted options, creating challenges for the patient and clinician.

Learning Objectives:

1. Identify which patients with large congenital melanocytic nevi (LCMN) are at risk for developing neurocutaneous melanocytosis (NCM)
2. Outline screening recommendations for high-risk patients
3. Review the molecular drivers of NCM associated melanoma
4. Review possible therapies for patients with NCM and or melanoma